Building a GCT Portfolio - 2021 World Medical Innovation Forum
May 19–21, 2021

Building a GCT Portfolio

Building a GCT Portfolio

Thursday, May 20, 2021

12:35 PM – 12:55 PM

GCT represents a large and growing market for novel therapeutics that has several segments. These include Cardiovascular Disease, Cancer, Neurological Diseases, Infectious Disease, Ophthalmology, Benign Blood Disorders, and many others; Manufacturing and Supply Chain including CDMO’s and CMO’s; Stem Cells and Regenerative Medicine; Tools and Platforms (viral vectors, nano delivery, gene editing, etc.). Bayer’s pharma business participates in virtually all of these segments. How does a Company like Bayer approach the development of a portfolio in a space as large and as diverse as this one? How does Bayer approach the support of the production infrastructure with unique demands and significant differences from its historical requirements?

Ansbert Gadicke, MD
  • Co-Founder, Managing Director, MPM Capital
Wolfram Carius, PhD
  • EVP, Pharmaceuticals, Head of Cell & Gene Therapy, Bayer AG
  • Q&A

    01:00 PM – 01:15 PM

the Future of Medicine and AI

May 11–13, 2020 | Boston, MA